Xencor, Inc. (XNCR) Reaches $40.89 After 8.00% Down Move; Encompass Capital Advisors Trimmed Energy Recovery (ERII) Stake By $1.89 Million

June 14, 2018 - By Migdalia James

Energy Recovery, Inc. (NASDAQ:ERII) Logo

Encompass Capital Advisors Llc decreased Energy Recovery Inc (ERII) stake by 19.59% reported in 2018Q1 SEC filing. Encompass Capital Advisors Llc sold 236,800 shares as Energy Recovery Inc (ERII)’s stock rose 9.11%. The Encompass Capital Advisors Llc holds 971,874 shares with $7.99M value, down from 1.21 million last quarter. Energy Recovery Inc now has $441.68M valuation. The stock decreased 5.22% or $0.4549 during the last trading session, reaching $8.2551. About 886,879 shares traded or 154.75% up from the average. Energy Recovery, Inc. (NASDAQ:ERII) has risen 5.14% since June 14, 2017 and is uptrending. It has underperformed by 7.43% the S&P500. Some Historical ERII News: ; 15/03/2018 – ENERGY RECOVERY – ORDERS EXPECTED TO SHIP IN H1 2018; 03/05/2018 – Energy Recovery 1Q Adj EPS 1c; 25/04/2018 – ELKEM ASA ELK.OL – ENERGY RECOVERY PLANT WILL HAVE AN ESTIMATED INVESTMENT FRAME OF UP TO NOK 1 BLN; 19/04/2018 – DJ Energy Recovery Inc, Inst Holders, 1Q 2018 (ERII); 25/05/2018 – PENNON GROUP – CONTINUE TO EXPECT UK RESIDUAL WASTE MARKET DYNAMICS TO BE FAVOURABLE WITH DEMAND FOR ENERGY RECOVERY FACILITIES EXCEEDING CAPACITY INTO LONG TERM; 23/04/2018 – First Trust Advisors Buys New 1% Position in Energy Recovery; 25/04/2018 – ELKEM ASA ELK.OL – SALTEN ENERGIGJENVINNING AS DECIDED TO BUILD AN ENERGY RECOVERY PLANT AT ELKEM SALTEN; 08/03/2018 – Energy Recovery Announces Share Repurchase Program; 02/05/2018 – Energy Recovery Access Event Scheduled By B. Riley FBR, Inc; 03/05/2018 – ENERGY RECOVERY NAMES CHRIS GANNON AS PRESIDENT & CEO

The stock of Xencor, Inc. (NASDAQ:XNCR) is a huge mover today! The stock decreased 1.78% or $0.74 during the last trading session, reaching $40.89. About 194,761 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 82.34% since June 14, 2017 and is uptrending. It has outperformed by 69.77% the S&P500. Some Historical XNCR News: ; 07/05/2018 – XENCOR INC – EXPECTS TO END 2018 WITH APPROXIMATELY $500 MLN IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES; 18/04/2018 – Applied BioMath, LLC Collaborates with Xencor for Semi-Mechanistic PK/PD Modeling of XmAb®24306, Xencor’s Lead lL15 Program for the Treatment of Solid Tumors; 18/04/2018 – Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer; 07/05/2018 – Xencor 1Q Rev $0.00; 08/05/2018 – Xencor at Deutsche Bank Health Care Conference Tomorrow; 07/05/2018 – XENCOR INC – EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2023; 07/05/2018 – BVF Buys New 1.6% Position in Xencor; 19/04/2018 – DJ Xencor Inc, Inst Holders, 1Q 2018 (XNCR); 10/04/2018 – Xencor Presenting at Deutsche Bank Health Care Conference May 9; 20/03/2018 – Xencor Announces Pricing of Public Offering of Common StkThe move comes after 7 months negative chart setup for the $2.28 billion company. It was reported on Jun, 14 by Barchart.com. We have $37.62 PT which if reached, will make NASDAQ:XNCR worth $182.00 million less.

More news for Energy Recovery, Inc. (NASDAQ:ERII) were recently published by: Benzinga.com, which released: “31 Stocks Moving In Thursday’s Mid-Day Session” on June 14, 2018. Seekingalpha.com‘s article titled: “Don’t Expect A Recovery From Energy Recovery” and published on May 22, 2018 is yet another important article.

Investors sentiment decreased to 1.1 in Q1 2018. Its down 0.59, from 1.69 in 2017Q4. It fall, as 16 investors sold ERII shares while 25 reduced holdings. 14 funds opened positions while 31 raised stakes. 18.16 million shares or 4.99% more from 17.30 million shares in 2017Q4 were reported. Tiaa Cref Inv Mngmt Ltd Liability Com has invested 0% in Energy Recovery, Inc. (NASDAQ:ERII). Whittier Comm holds 0% or 2,099 shares. Prelude Ltd Company reported 0.01% in Energy Recovery, Inc. (NASDAQ:ERII). Moreover, Vanguard Inc has 0% invested in Energy Recovery, Inc. (NASDAQ:ERII) for 1.66 million shares. Fuller Thaler Asset owns 0.03% invested in Energy Recovery, Inc. (NASDAQ:ERII) for 278,304 shares. Essex Inv Management Ltd Llc reported 321,543 shares. Metropolitan Life Ny holds 7,979 shares. Glenmede Trust Com Na stated it has 2,500 shares or 0% of all its holdings. Parallax Volatility Advisers Ltd Partnership, a California-based fund reported 5,878 shares. Gp One Trading Lp reported 0.01% stake. Neuberger Berman Group Llc, a New York-based fund reported 60,000 shares. Cambridge Invest owns 23,078 shares. Swiss Retail Bank reported 0% in Energy Recovery, Inc. (NASDAQ:ERII). Corecommodity Management reported 45,271 shares. Bancorporation Of Montreal Can accumulated 0% or 12,600 shares.

Among 7 analysts covering Energy Recovery (NASDAQ:ERII), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Energy Recovery had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained the shares of ERII in report on Tuesday, October 17 with “Buy” rating. The stock has “Outperform” rating by Iberia Capital Partners on Monday, September 26. Credit Suisse upgraded Energy Recovery, Inc. (NASDAQ:ERII) on Wednesday, October 21 to “Outperform” rating. FBR Capital maintained Energy Recovery, Inc. (NASDAQ:ERII) rating on Wednesday, November 8. FBR Capital has “Buy” rating and $20.0 target. The firm has “Buy” rating given on Tuesday, March 27 by FBR Capital. On Friday, July 15 the stock rating was initiated by FBR Capital with “Outperform”. iBERIA Capital Partners initiated it with “Outperform” rating and $21 target in Monday, September 26 report. The stock has “Buy” rating by FBR Capital on Thursday, November 30. The firm has “Buy” rating by Jefferies given on Tuesday, September 13. As per Monday, August 28, the company rating was maintained by FBR Capital.

Since March 12, 2018, it had 0 insider buys, and 1 sale for $428,300 activity. Another trade for 50,000 shares valued at $428,300 was made by Hanstveit Arve on Monday, March 12.

Analysts await Energy Recovery, Inc. (NASDAQ:ERII) to report earnings on August, 1. They expect $0.01 earnings per share, up 200.00% or $0.02 from last year’s $-0.01 per share. ERII’s profit will be $535,034 for 206.38 P/E if the $0.01 EPS becomes a reality. After $0.01 actual earnings per share reported by Energy Recovery, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 1.7 in 2018 Q1. Its up 0.49, from 1.21 in 2017Q4. It is positive, as 7 investors sold Xencor, Inc. shares while 30 reduced holdings. 28 funds opened positions while 35 raised stakes. 43.81 million shares or 19.94% more from 36.52 million shares in 2017Q4 were reported. Franklin Resources has invested 0.01% in Xencor, Inc. (NASDAQ:XNCR). Artal Grp Inc Sa stated it has 300,000 shares. Arrowmark Colorado Liability Corporation owns 541,563 shares. Farallon Cap Management Limited Liability Co has 149,900 shares. Renaissance Technology Limited Liability Co holds 0% or 55,600 shares in its portfolio. Bailard Inc has invested 0.04% in Xencor, Inc. (NASDAQ:XNCR). Pub Employees Retirement Association Of Colorado holds 0% or 2,674 shares in its portfolio. Virginia Retirement Et Al accumulated 0.01% or 34,400 shares. 202,874 were reported by Schwab Charles Investment Management Incorporated. Birchview Capital L P owns 0.24% invested in Xencor, Inc. (NASDAQ:XNCR) for 12,300 shares. International Grp Incorporated owns 24,344 shares. Dekabank Deutsche Girozentrale holds 18,700 shares. Morgan Stanley invested in 0% or 87,410 shares. Pointstate Capital Limited Partnership has 0.16% invested in Xencor, Inc. (NASDAQ:XNCR) for 477,000 shares. Jpmorgan Chase & Com invested in 248,917 shares or 0% of the stock.

Among 9 analysts covering Xencor (NASDAQ:XNCR), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Xencor had 25 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Sunday, November 12 by Piper Jaffray. On Tuesday, May 8 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating by Canaccord Genuity given on Monday, August 7. On Thursday, March 29 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm earned “Outperform” rating on Monday, March 19 by Wedbush. The firm earned “Overweight” rating on Tuesday, October 4 by Piper Jaffray. The firm earned “Hold” rating on Friday, September 4 by Zacks. As per Thursday, February 22, the company rating was initiated by Cantor Fitzgerald. The firm has “Outperform” rating given on Thursday, September 17 by Leerink Swann. As per Wednesday, March 28, the company rating was initiated by Leerink Swann.

More recent Xencor, Inc. (NASDAQ:XNCR) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 07, 2018. Also Streetinsider.com published the news titled: “BTIG Starts Xencor, Inc. (XNCR) at Buy” on June 06, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” with publication date: May 25, 2018 was also an interesting one.

Since February 16, 2018, it had 0 insider buys, and 6 sales for $3.02 million activity. Foster Paul A also sold $125,050 worth of Xencor, Inc. (NASDAQ:XNCR) shares. The insider Baracchini Edgardo Jr sold 20,000 shares worth $591,806.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $2.28 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Analysts await Xencor, Inc. (NASDAQ:XNCR) to report earnings on August, 6. They expect $-0.55 earnings per share, down 266.67% or $0.40 from last year’s $-0.15 per share. After $-0.62 actual earnings per share reported by Xencor, Inc. for the previous quarter, Wall Street now forecasts -11.29% EPS growth.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts